Novartis

Novartis-partnered Orionis secures $55M to push cytokine program into clinic
Endpoints
Wed, 10/19/22 - 10:55 am
Orionis Biosciences
Novartis
funding
R&D
cytokines
Novartis, GSK and Sanofi Scale Back on Operations and Labor Forces Overseas - Updated
BioSpace
Mon, 10/17/22 - 10:46 am
Novartis
GSK
Sanofi
layoffs
Novartis' blockbuster Gilenya exposed to generics in short term amid Supreme Court appeal
Fierce Pharma
Fri, 10/14/22 - 10:40 am
Novartis
Gilenya
generics
Supreme Court
MS
multiple sclerosis
Novartis to lay off 400 at Dublin campus amid global restructuring
Fierce Pharma
Fri, 10/14/22 - 10:05 am
Novartis
Ireland
layoffs
restructuring
Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper
BioSpace
Wed, 10/12/22 - 11:45 pm
Novartis
Zolgensma
data manipulation
SMA
Sun, Camber join growing list of companies reporting Adderall supply problems
Fierce Pharma
Fri, 10/7/22 - 10:50 am
ADHD
Adderall
drug shortages
Sandoz
Sun Pharma
Novartis
BioSpace Layoff Tracker 2022: Cyclerion, OncoSec Implement Restructuring Initiatives
BioSpace
Fri, 10/7/22 - 10:45 am
layoffs
Cyclerion
OncoSec
Exicure
AbbVie
Bristol Myers Squibb
Palisade Bio
ObsEva
Rubius Therapeutics
Novartis
Finch Therapeutics
Go or no go? GSK takes its turn with a novel anemia class
EP Vantage
Fri, 09/30/22 - 10:52 am
FDA
GSK
Amicus Therapeutics
AstraZeneca
Novartis
Supernus
JNJ
Ipsen
Y-mAbs Therapeutics
Former Novartis drug for ultra-rare disease gets speedy FDA review
Endpoints
Wed, 09/28/22 - 10:58 am
Pharming
Novartis
leniolisib
APDS
FDA
MHRA raises concerns with switching between long-acting J&J, Novartis and Takeda ADHD drugs
Fierce Pharma
Tue, 09/27/22 - 10:37 am
Takeda
JNJ
Novartis
ADHD
MHRA
Concerta XL
Ritalin XL
Equasym XL
PCSK9 pipeline shows signs of saturation
EP Vantage
Tue, 09/27/22 - 10:21 am
AstraZeneca
ION449
Ionis Pharmaceuticals
Novartis
Leqvio
PCSK9 inhibitors
Novartis wins on quantity, but Eli Lilly takes the cake on value of new launches: report
Fierce Pharma
Mon, 09/26/22 - 11:04 am
Novartis
Eli Lilly
drug launches
Mounjaro
Novartis Unveils Path to Becoming a Top 5 US Player by 2027
BioSpace
Thu, 09/22/22 - 11:17 pm
Novartis
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court
Fierce Pharma
Wed, 09/21/22 - 08:02 pm
Novartis
Supreme Court
Gilenya
patents
legal
MS
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Tue, 09/20/22 - 08:36 pm
Biogen
Novartis
Sandoz
biosimilars
Tysabri
MS
multiple sclerosis
Sandoz reports data from Phase I/III trial of denosumab for osteoporosis
Clinical Trials Arena
Tue, 09/20/22 - 10:07 am
Novartis
Sandoz
clinical trials
biosimilarts
denosumab
osteoporosis
Novartis investing US$300m in next generation biotherapeutics development
Biopharma Reporter
Mon, 09/19/22 - 09:14 am
Novartis
biologics
biotherapeutics
drug development
Novartis headquarters raided in Swiss competition authority's patent probe
Fierce Pharma
Thu, 09/15/22 - 10:54 am
Novartis
Switzerland
patents
competition
Novartis dodges Gilenya kickback claims—again—after whistleblower lawsuit dismissed
Fierce Pharma
Wed, 09/14/22 - 08:04 pm
Novartis
whistleblowers
whistleblower lawsuit
Gilenya
kickbacks
MS
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?
Fierce Pharma
Tue, 09/13/22 - 08:03 pm
Novartis
FDA
Cosentyx
AbbVie
Humira
hidradenitis suppurativa

Pages